董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Joseph Klein, III | 男 | Director | 64 | 70.74万美元 | 未持股 | 2017-02-21 |
| Spencer R. Berthelsen | 男 | Director | 73 | 73.24万美元 | 未持股 | 2017-02-21 |
| B. Lynne Parshall | 女 | Director, Chief Operating Officer and Secretary | 62 | 636.14万美元 | 未持股 | 2017-02-21 |
| Joseph H. Wender | 男 | Director | 80 | 未披露 | 未持股 | 2017-02-21 |
| Frederick T. Muto | 男 | Director | 71 | 70.24万美元 | 未持股 | 2017-02-21 |
| Stanley T. Crooke | 男 | Chairman, Chief Executive Officer and President | 71 | 798.10万美元 | 未持股 | 2017-02-21 |
| Joseph H. Wender | 男 | Director | 80 | 73.39万美元 | 未持股 | 2017-02-21 |
| Joseph Loscalzo | 男 | Director | 73 | 71.62万美元 | 未持股 | 2017-02-21 |
| Breaux B. Castleman | 男 | Director | 84 | 70.74万美元 | 未持股 | 2017-02-21 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Sarah Boyce | 女 | Chief Business Officer | 45 | 290.65万美元 | 未持股 | 2017-02-21 |
| B. Lynne Parshall | 女 | Director, Chief Operating Officer and Secretary | 62 | 636.14万美元 | 未持股 | 2017-02-21 |
| C. Frank Bennett | 男 | Senior Vice President, Antisense Research | 60 | 95.89万美元 | 未持股 | 2017-02-21 |
| Richard S. Geary | 男 | Senior Vice President, Development | 59 | 178.59万美元 | 未持股 | 2017-02-21 |
| Stanley T. Crooke | 男 | Chairman, Chief Executive Officer and President | 71 | 798.10万美元 | 未持股 | 2017-02-21 |
| Elizabeth L. Hougen | 女 | Senior Vice President, Finance and Chief Financial Officer | 55 | 192.99万美元 | 未持股 | 2017-02-21 |
| Brett P. Monia | 男 | Senior Vice President, Drug Discovery and Corporate Development | 55 | 211.20万美元 | 未持股 | 2017-02-21 |
| Patrick R. O'Neil | 男 | Senior Vice President, Legal, General Counsel, Chief Compliance Officer and Corporate Secretary | 43 | 未披露 | 未持股 | 2017-02-21 |
董事简历
中英对照 | 中文 | 英文- Joseph Klein, III
-
Joseph Klein, III，2005年12月起，他担任Isis的董事。目前，他是 Gauss Capital Advisors, LLC的董事总经理，这是一个财务咨询和投资顾问公司，专注于生物制药，是由他于1998年创立的。自2003年9月至2008年12月，他担任Red Abbey Venture Partners, L.P的风险合伙人，这是一个生命科学私募股权基金公司。自2001年9月至2002年9月，他是 MPM Capital的风险合伙人，这是一个医疗保健风险资本公司。自1999年6月至2000年9月Medical Manager Corporation与 WebMD Corporation合并，他一直担任其战略部门副总裁，这是一个领先的医学办公管理信息系统的开发商。1989年至1998年超过9年的时间里，他是 T. Rowe Price Associates, Inc.的医疗保健投资分析师，在那里他是the T. Rowe Price Health Sciences Fund, Inc. 的证券投资组合创始经理。他任职于The Prospector Funds, Inc.董事会，这是一个证券交易委员会注册的投资公司，管理两个亿资产净值出售的基金会。他还任职于5个上市的生物技术公司的董事会： BioMarin Pharmaceutical Inc., NPS Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., PDL BioPharma, Inc. 和 Savient Pharmaceuticals, Inc.。
Joseph Klein, III has served as a Director of Ionis since December 2005. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008 Mr. Klein also served as a Venture Partner of Red Abbey Venture Partners, L.P., a life science private equity fund. From September 2001 to September 2002 Mr. Klein was a Venture Partner of MPM Capital, a healthcare venture capital firm. From June 1999 to September 2000 when it merged with WebMD Corporation, Mr. Klein served as Vice President, Strategy, for Medical Manager Corporation, a leading developer of physician office management information systems. For over nine years from 1989 to 1998 Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. Mr. Klein serves on the board of directors of The Prospector Funds, Inc., an SEC Registered Investment Company that manages two no-load mutual funds. Mr. Klein also serves on the boards of private and non-profit entities. Within the last five years, Mr. Klein formerly served on the board of directors of five publicly held biotechnology companies: BioMarin Pharmaceutical Inc., NPS Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., PDL BioPharma, Inc. and Savient Pharmaceuticals, Inc. - Joseph Klein, III，2005年12月起，他担任Isis的董事。目前，他是 Gauss Capital Advisors, LLC的董事总经理，这是一个财务咨询和投资顾问公司，专注于生物制药，是由他于1998年创立的。自2003年9月至2008年12月，他担任Red Abbey Venture Partners, L.P的风险合伙人，这是一个生命科学私募股权基金公司。自2001年9月至2002年9月，他是 MPM Capital的风险合伙人，这是一个医疗保健风险资本公司。自1999年6月至2000年9月Medical Manager Corporation与 WebMD Corporation合并，他一直担任其战略部门副总裁，这是一个领先的医学办公管理信息系统的开发商。1989年至1998年超过9年的时间里，他是 T. Rowe Price Associates, Inc.的医疗保健投资分析师，在那里他是the T. Rowe Price Health Sciences Fund, Inc. 的证券投资组合创始经理。他任职于The Prospector Funds, Inc.董事会，这是一个证券交易委员会注册的投资公司，管理两个亿资产净值出售的基金会。他还任职于5个上市的生物技术公司的董事会： BioMarin Pharmaceutical Inc., NPS Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., PDL BioPharma, Inc. 和 Savient Pharmaceuticals, Inc.。
- Joseph Klein, III has served as a Director of Ionis since December 2005. Mr. Klein is currently Managing Director of Gauss Capital Advisors, LLC, a financial consulting and investment advisory firm focused on biopharmaceuticals, which he founded in March 1998. From September 2003 to December 2008 Mr. Klein also served as a Venture Partner of Red Abbey Venture Partners, L.P., a life science private equity fund. From September 2001 to September 2002 Mr. Klein was a Venture Partner of MPM Capital, a healthcare venture capital firm. From June 1999 to September 2000 when it merged with WebMD Corporation, Mr. Klein served as Vice President, Strategy, for Medical Manager Corporation, a leading developer of physician office management information systems. For over nine years from 1989 to 1998 Mr. Klein was a health care investment analyst at T. Rowe Price Associates, Inc., where he was the founding portfolio manager of the T. Rowe Price Health Sciences Fund, Inc. Mr. Klein serves on the board of directors of The Prospector Funds, Inc., an SEC Registered Investment Company that manages two no-load mutual funds. Mr. Klein also serves on the boards of private and non-profit entities. Within the last five years, Mr. Klein formerly served on the board of directors of five publicly held biotechnology companies: BioMarin Pharmaceutical Inc., NPS Pharmaceuticals, Inc., OSI Pharmaceuticals, Inc., PDL BioPharma, Inc. and Savient Pharmaceuticals, Inc.
- Spencer R. Berthelsen
-
Spencer R. Berthelsen，自2002年起，他一直担任Isis的董事。自1980年起，他一直参与the Kelsey Seybold Clinic内科医学的实践，这是一个位于休斯敦得克萨斯医疗中心的拥有370个医生的医疗部门。他在 Kelsey Seybold，担任过许多高级领导类的职务，包括自2001年10月起担任他们的董事长。他在Baylor College of Medicine 和 the University of Texas Health Science Center of Houston。担任一名医学临床教授。过去他任职于 the Texas Academy of Internal Medicine的董事会；1999年至2005年，他任职于the Caremark National Pharmacy and Therapeutics Committee。
Spencer R. Berthelsen has served as a Director of Ionis since May 2002. Since 1980 he has practiced Internal Medicine with the Kelsey Seybold Clinic, a 400 physician medical group based in the Texas Medical Center in Houston. Dr. Berthelsen has served in various senior leadership positions at Kelsey Seybold, including Chairman of the Department of Internal Medicine, Medical Director and Managing Director. He has been Chairman of their Board of Directors since October 2001. He has served as a Clinical Professor of Medicine at Baylor College of Medicine and the University of Texas Health Science Center of Houston. Dr. Berthelsen served on the board of the Texas Academy of Internal Medicine in the past and the Caremark National Pharmacy and Therapeutics Committee from 1999 through 2005. - Spencer R. Berthelsen，自2002年起，他一直担任Isis的董事。自1980年起，他一直参与the Kelsey Seybold Clinic内科医学的实践，这是一个位于休斯敦得克萨斯医疗中心的拥有370个医生的医疗部门。他在 Kelsey Seybold，担任过许多高级领导类的职务，包括自2001年10月起担任他们的董事长。他在Baylor College of Medicine 和 the University of Texas Health Science Center of Houston。担任一名医学临床教授。过去他任职于 the Texas Academy of Internal Medicine的董事会；1999年至2005年，他任职于the Caremark National Pharmacy and Therapeutics Committee。
- Spencer R. Berthelsen has served as a Director of Ionis since May 2002. Since 1980 he has practiced Internal Medicine with the Kelsey Seybold Clinic, a 400 physician medical group based in the Texas Medical Center in Houston. Dr. Berthelsen has served in various senior leadership positions at Kelsey Seybold, including Chairman of the Department of Internal Medicine, Medical Director and Managing Director. He has been Chairman of their Board of Directors since October 2001. He has served as a Clinical Professor of Medicine at Baylor College of Medicine and the University of Texas Health Science Center of Houston. Dr. Berthelsen served on the board of the Texas Academy of Internal Medicine in the past and the Caremark National Pharmacy and Therapeutics Committee from 1999 through 2005.
- B. Lynne Parshall
-
B. Lynne Parshall， 2013年2月起担任董事会成员。她目前担任Ionis Pharmaceuticals， Inc.和Foghorn Therapeutics Inc.的董事会成员。Parshall女士于1991年至2017年在Ionis任职，在那里她担任过各种职务。在加入Ionis之前，她是Cooley LLP律师事务所的合伙人。Parshall女士自2021年12月起担任私营生命科学公司Repetoir Immune Medicines， Inc.的董事会成员；自2022年3月起担任私营生命科学公司Ring Therapeutics的董事会成员；自2022年8月起担任Foghorn Therapeutics的董事会成员；自2023年起担任私营公司Alltrna和Celdeara Medical的董事会成员。Parshall女士从2015年到2020年10月担任Akcea Therapeutics Inc.的董事会成员。Parshall女士是the Licensing Executives Society的成员，也是美国、加州和圣地亚哥律师协会的成员。她拥有斯坦福大学法学院的法学博士学位和哈佛大学的学士学位。
B. Lynne Parshall,has served as a member of Board of Directors since February 2013. She currently serves as a member of the Board of Directors of Ionis Pharmaceuticals, Inc. and Foghorn Therapeutics Inc. Ms. Parshall was employed at Ionis from 1991 to 2017 where she held various positions of increasing responsibility. Prior to joining Ionis, she was a partner at the law firm of Cooley LLP. Ms. Parshall has served on the Board of Directors of Repetoir Immune Medicines, Inc., a private life sciences company, since December 2021, Ring Therapeutics, a private life sciences company, since March 2022 and Foghorn Therapeutics since August 2022 and each of Alltrna and Celdeara Medical, both private companies, since 2023. Ms. Parshall served as a member of the Board of Directors of Akcea Therapeutics Inc. from 2015 to October 2020. Ms. Parshall is a member of the Licensing Executives Society and a member of the American, California and San Diego bar associations. She holds a J.D. from Stanford Law School and a B.A. from Harvard University. - B. Lynne Parshall， 2013年2月起担任董事会成员。她目前担任Ionis Pharmaceuticals， Inc.和Foghorn Therapeutics Inc.的董事会成员。Parshall女士于1991年至2017年在Ionis任职，在那里她担任过各种职务。在加入Ionis之前，她是Cooley LLP律师事务所的合伙人。Parshall女士自2021年12月起担任私营生命科学公司Repetoir Immune Medicines， Inc.的董事会成员；自2022年3月起担任私营生命科学公司Ring Therapeutics的董事会成员；自2022年8月起担任Foghorn Therapeutics的董事会成员；自2023年起担任私营公司Alltrna和Celdeara Medical的董事会成员。Parshall女士从2015年到2020年10月担任Akcea Therapeutics Inc.的董事会成员。Parshall女士是the Licensing Executives Society的成员，也是美国、加州和圣地亚哥律师协会的成员。她拥有斯坦福大学法学院的法学博士学位和哈佛大学的学士学位。
- B. Lynne Parshall,has served as a member of Board of Directors since February 2013. She currently serves as a member of the Board of Directors of Ionis Pharmaceuticals, Inc. and Foghorn Therapeutics Inc. Ms. Parshall was employed at Ionis from 1991 to 2017 where she held various positions of increasing responsibility. Prior to joining Ionis, she was a partner at the law firm of Cooley LLP. Ms. Parshall has served on the Board of Directors of Repetoir Immune Medicines, Inc., a private life sciences company, since December 2021, Ring Therapeutics, a private life sciences company, since March 2022 and Foghorn Therapeutics since August 2022 and each of Alltrna and Celdeara Medical, both private companies, since 2023. Ms. Parshall served as a member of the Board of Directors of Akcea Therapeutics Inc. from 2015 to October 2020. Ms. Parshall is a member of the Licensing Executives Society and a member of the American, California and San Diego bar associations. She holds a J.D. from Stanford Law School and a B.A. from Harvard University.
- Joseph H. Wender
-
Joseph H. Wender,自1994年1月起，他一直担任Isis的董事。1971年他创立了 Goldman, Sachs & Co.；1982年成为该公司的普通合伙人，在那里他领导非银行金融机构部门超过10年。自2008年1月起，他一直担任 Goldman Sachs & Co.的高级顾问。他还是Schwab Family of Funds 的独立董事，以及 Grandpoint Capital（一个银行股份公司）的董事。他和他的妻子，Colgin Cellars，还是任事股东和所有者。一直到2014年3月，他是 CBS Outdoors America Inc.的董事，这是一个为户外广告的结构做广告的出租公司。
Joseph H. Wender has served as a Director of Ionis since January 1994. Mr. Wender began with Goldman, Sachs & Co. in 1971 and became a General Partner of that firm in 1982 where he headed the Financial Institutions Group for over a decade. Since January 2008 he has been a Senior Consultant to Goldman Sachs & Co. He is also an Independent Trustee of the Schwab Family of Funds and Director of Grandpoint Capital, a bank holding company. Mr. Wender also is a managing partner and owns, with his wife, Colgin Cellars. Since March 2014 Mr. Wender has been a director of Outfront Media, lessors of advertising space on out-of-home advertising structures. - Joseph H. Wender,自1994年1月起，他一直担任Isis的董事。1971年他创立了 Goldman, Sachs & Co.；1982年成为该公司的普通合伙人，在那里他领导非银行金融机构部门超过10年。自2008年1月起，他一直担任 Goldman Sachs & Co.的高级顾问。他还是Schwab Family of Funds 的独立董事，以及 Grandpoint Capital（一个银行股份公司）的董事。他和他的妻子，Colgin Cellars，还是任事股东和所有者。一直到2014年3月，他是 CBS Outdoors America Inc.的董事，这是一个为户外广告的结构做广告的出租公司。
- Joseph H. Wender has served as a Director of Ionis since January 1994. Mr. Wender began with Goldman, Sachs & Co. in 1971 and became a General Partner of that firm in 1982 where he headed the Financial Institutions Group for over a decade. Since January 2008 he has been a Senior Consultant to Goldman Sachs & Co. He is also an Independent Trustee of the Schwab Family of Funds and Director of Grandpoint Capital, a bank holding company. Mr. Wender also is a managing partner and owns, with his wife, Colgin Cellars. Since March 2014 Mr. Wender has been a director of Outfront Media, lessors of advertising space on out-of-home advertising structures.
- Frederick T. Muto
-
Frederick T. Muto，自2001年3月起，他一直担任Isis的董事。1980年他加入法律公司 Cooley LLP，Isis的外部法律顾问；1986年成为合伙人。他是公司的业务部门的主席，以及Cooley LLP的圣地亚哥办公室的创始合伙人。
Frederick T. Muto has served as a Director of Ionis since March 2001. Mr. Muto joined the law firm of Cooley LLP, outside counsel to Ionis, in 1980 and became a partner in 1986. He is Chair of the firm’s Business Department and a founding partner of Cooley LLP’s San Diego office. - Frederick T. Muto，自2001年3月起，他一直担任Isis的董事。1980年他加入法律公司 Cooley LLP，Isis的外部法律顾问；1986年成为合伙人。他是公司的业务部门的主席，以及Cooley LLP的圣地亚哥办公室的创始合伙人。
- Frederick T. Muto has served as a Director of Ionis since March 2001. Mr. Muto joined the law firm of Cooley LLP, outside counsel to Ionis, in 1980 and became a partner in 1986. He is Chair of the firm’s Business Department and a founding partner of Cooley LLP’s San Diego office.
- Stanley T. Crooke
-
Stanley T. Crooke, M.D., Ph.D.，2009年1月我们公司成立，他在我们董事会任职。此前2007年11月以来，他担任Regulus Therapeutics LLC的董事。他加入我们董事会并担任伊希斯的代表并在2009年1月1日或我们创立投资者权利协议时，他按照建立投资者权利协议进行投资（Alnylam和Isis）。他是Isis的创始人，并担任其首席执行官和董事（1989年以来）以及董事长（1991年以来）。他获得贝勒医学院（Baylor College of Medicine） 药物学硕士和博士学位以及巴特勒大学（Butler University）的药物学学士学位。
Stanley T. Crooke is a founder of Ionis and has been Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Ionis, from 1980 until January 1989 Dr. Crooke was employed by SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories. - Stanley T. Crooke, M.D., Ph.D.，2009年1月我们公司成立，他在我们董事会任职。此前2007年11月以来，他担任Regulus Therapeutics LLC的董事。他加入我们董事会并担任伊希斯的代表并在2009年1月1日或我们创立投资者权利协议时，他按照建立投资者权利协议进行投资（Alnylam和Isis）。他是Isis的创始人，并担任其首席执行官和董事（1989年以来）以及董事长（1991年以来）。他获得贝勒医学院（Baylor College of Medicine） 药物学硕士和博士学位以及巴特勒大学（Butler University）的药物学学士学位。
- Stanley T. Crooke is a founder of Ionis and has been Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Ionis, from 1980 until January 1989 Dr. Crooke was employed by SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories.
- Joseph H. Wender
-
Joseph H. Wender，2008年1月起，他担任高盛公司（Goldman Sachs & Co. ）的高级顾问。1971年，他加入高盛公司；1982年成为公司普通合伙人，并且主管Financial Institutions Group 超过10年。他目前是Isis Pharmaceuticals and Grandpoint Capital的董事，该公司是银行控股公司，也是施瓦布家族的一个独立的信托基金。
Joseph H. Wender,has served on the Board since March 2014, and has served as Lead Independent Director since February 2015. He has served as an Advisory Director and as a Senior Consultant to Goldman Sachs & Co. LLC since January 2008. He began with Goldman Sachs & Co. LLC in 1971 and became General Partner of the firm in 1982, at which time he headed the Financial Institutions Group for over a decade. Mr. Wender also currently serves as a director as well as on the finance, compensation and nominating, governance and review committees of Ionis Pharmaceuticals, Inc. Mr. Wender served as a director of Grandpoint Capital, a bank holding company from January 2008 to June 2018 and as an Independent Trustee of the Schwab Family of Funds until December 2018. - Joseph H. Wender，2008年1月起，他担任高盛公司（Goldman Sachs & Co. ）的高级顾问。1971年，他加入高盛公司；1982年成为公司普通合伙人，并且主管Financial Institutions Group 超过10年。他目前是Isis Pharmaceuticals and Grandpoint Capital的董事，该公司是银行控股公司，也是施瓦布家族的一个独立的信托基金。
- Joseph H. Wender,has served on the Board since March 2014, and has served as Lead Independent Director since February 2015. He has served as an Advisory Director and as a Senior Consultant to Goldman Sachs & Co. LLC since January 2008. He began with Goldman Sachs & Co. LLC in 1971 and became General Partner of the firm in 1982, at which time he headed the Financial Institutions Group for over a decade. Mr. Wender also currently serves as a director as well as on the finance, compensation and nominating, governance and review committees of Ionis Pharmaceuticals, Inc. Mr. Wender served as a director of Grandpoint Capital, a bank holding company from January 2008 to June 2018 and as an Independent Trustee of the Schwab Family of Funds until December 2018.
- Joseph Loscalzo
-
Joseph Loscalzo自2016年起担任董事会成员。现任哈佛大学医学院Hersey医学理论与实践教授，Brigham and Women's医院医学系主任、主任医师。1994年，Loscalso博士加入波士顿大学，首先担任心脏病学主任，并于1997年担任Wade教授和医学主席、生物化学教授和Whitaker心血管研究所所长。2005年，他回到哈佛医学院和Brigham and Women's医院，此前他曾在那里工作。他曾在多个美国国立卫生研究院研究部门和编辑委员会任职，并主持了关于溶栓的Gordon会议。他是《新英格兰医学杂志》的特约编辑，曾任美国内科医学委员会心血管委员会主席，曾任美国心脏协会研究委员会主席，曾任Stanley J. Sarnoff心血管科学研究员协会科学委员会主席，曾任美国国立卫生研究院国家心肺血液研究所科学顾问委员会主席。他是《循环》的前任主编，现任《哈里森内科学原理》高级编辑，曾任美国国家心肺血液研究所咨询委员会成员，曾任美国国立卫生研究院理事会成员。Loscalzo博士曾是多家机构的客座教授，拥有两个荣誉学位，撰写或合著了900多篇科学出版物，撰写或编辑了30本著作，并拥有其在一氧化氮领域工作的33项专利。由于过去三十年在血管生物学、血栓形成和动脉粥样硬化领域的工作，他还获得了美国国立卫生研究院和行业的许多资助，并获得了无数奖项。Loscalzo博士以优异成绩获得了AB学位、生物化学博士学位和宾夕法尼亚大学的医学博士学位，并在Brigham and Women's医院和哈佛医学院完成了临床培训，在那里他担任了医学住院医师和首席住院医师以及心血管医学研究员。Loscalzo博士目前是波士顿咨询公司和Momenta Pharmaceuticals, Inc.的顾问，是Broadview Ventures，Inc.、赛诺菲 S.A.、DZZOM、The Network Medicine Company和Applied Biomath，LLC的科学顾问委员会成员，并且是Ionis Pharmaceuticals Inc. IONS：纳斯达克的董事会成员。
Joseph Loscalzo,has served as a member of Board since January 2016. He is currently the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, and Chairman of the Department of Medicine and Physician-in-Chief at Brigham and Women's Hospital. In 1994, Dr. Loscalzo joined the faculty of Boston University, first as Chief of Cardiology and, in 1997, as Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. In July 2005, he returned to Harvard Medical School and Brigham and Women's Hospital, where he had previously worked. He is an editor-at-large of the New England Journal of Medicine, former Chair of the Cardiovascular Board of the American Board of Internal Medicine, former Chair of the Research Committee of the American Heart Association, former Chair of the Scientific Board of the Stanley J. Sarnoff Society of Fellows for Research in Cardiovascular Sciences, and former Chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the National Institutes of Health. He is past Editor-in-Chief of Circulation, a current senior editor of Harrison's Principles of Internal Medicine, a former member of the Advisory Council of the National Heart, Lung, and Blood Institute, and a former member of the Council of Councils of the National Institutes of Health. Dr. Loscalzo received his AB degree, summa cum laude, his PhD in biochemistry, and his MD from the University of Pennsylvania and completed his clinical training at Brigham and Women's Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine. Dr. Loscalzo is currently a member of the board of directors of Ionis Pharmaceuticals Inc. (Nasdaq: IONS). - Joseph Loscalzo自2016年起担任董事会成员。现任哈佛大学医学院Hersey医学理论与实践教授，Brigham and Women's医院医学系主任、主任医师。1994年，Loscalso博士加入波士顿大学，首先担任心脏病学主任，并于1997年担任Wade教授和医学主席、生物化学教授和Whitaker心血管研究所所长。2005年，他回到哈佛医学院和Brigham and Women's医院，此前他曾在那里工作。他曾在多个美国国立卫生研究院研究部门和编辑委员会任职，并主持了关于溶栓的Gordon会议。他是《新英格兰医学杂志》的特约编辑，曾任美国内科医学委员会心血管委员会主席，曾任美国心脏协会研究委员会主席，曾任Stanley J. Sarnoff心血管科学研究员协会科学委员会主席，曾任美国国立卫生研究院国家心肺血液研究所科学顾问委员会主席。他是《循环》的前任主编，现任《哈里森内科学原理》高级编辑，曾任美国国家心肺血液研究所咨询委员会成员，曾任美国国立卫生研究院理事会成员。Loscalzo博士曾是多家机构的客座教授，拥有两个荣誉学位，撰写或合著了900多篇科学出版物，撰写或编辑了30本著作，并拥有其在一氧化氮领域工作的33项专利。由于过去三十年在血管生物学、血栓形成和动脉粥样硬化领域的工作，他还获得了美国国立卫生研究院和行业的许多资助，并获得了无数奖项。Loscalzo博士以优异成绩获得了AB学位、生物化学博士学位和宾夕法尼亚大学的医学博士学位，并在Brigham and Women's医院和哈佛医学院完成了临床培训，在那里他担任了医学住院医师和首席住院医师以及心血管医学研究员。Loscalzo博士目前是波士顿咨询公司和Momenta Pharmaceuticals, Inc.的顾问，是Broadview Ventures，Inc.、赛诺菲 S.A.、DZZOM、The Network Medicine Company和Applied Biomath，LLC的科学顾问委员会成员，并且是Ionis Pharmaceuticals Inc. IONS：纳斯达克的董事会成员。
- Joseph Loscalzo,has served as a member of Board since January 2016. He is currently the Hersey Professor of the Theory and Practice of Medicine at Harvard Medical School, and Chairman of the Department of Medicine and Physician-in-Chief at Brigham and Women's Hospital. In 1994, Dr. Loscalzo joined the faculty of Boston University, first as Chief of Cardiology and, in 1997, as Wade Professor and Chair of Medicine, Professor of Biochemistry, and Director of the Whitaker Cardiovascular Institute. In July 2005, he returned to Harvard Medical School and Brigham and Women's Hospital, where he had previously worked. He is an editor-at-large of the New England Journal of Medicine, former Chair of the Cardiovascular Board of the American Board of Internal Medicine, former Chair of the Research Committee of the American Heart Association, former Chair of the Scientific Board of the Stanley J. Sarnoff Society of Fellows for Research in Cardiovascular Sciences, and former Chair of the Board of Scientific Counselors of the National Heart, Lung, and Blood Institute of the National Institutes of Health. He is past Editor-in-Chief of Circulation, a current senior editor of Harrison's Principles of Internal Medicine, a former member of the Advisory Council of the National Heart, Lung, and Blood Institute, and a former member of the Council of Councils of the National Institutes of Health. Dr. Loscalzo received his AB degree, summa cum laude, his PhD in biochemistry, and his MD from the University of Pennsylvania and completed his clinical training at Brigham and Women's Hospital and Harvard Medical School, where he served as Resident and Chief Resident in medicine and Fellow in cardiovascular medicine. Dr. Loscalzo is currently a member of the board of directors of Ionis Pharmaceuticals Inc. (Nasdaq: IONS).
- Breaux B. Castleman
-
Breaux B. Castleman，自2013年6月起，他一直担任Isis的董事。自2011年8月起，他担任 Syntiro Healthcare Services, Inc.的总裁和首席执行官，这是一个卫生保健投资公司，最近它将其经营权作为一个综合护理管理和疾病管理的服务供应商出售。自2009年9月起，他担任USMD Holdings, Inc.的董事，这是一个医生领导的综合保健系统公司。自2003年至2011年，他担任 MELA Sciences, Inc.的董事，这是一个医疗设备公司。
Breaux B. Castleman has served as a Director of Ionis since June 2013. Since August 2001 Mr. Castleman has been president and chief executive officer of Syntiro Healthcare Services, Inc., a healthcare investment company, which sold its operations as a service provider of integrated care management and disease management. Mr. Castleman has been a director of USMD Holdings, Inc., a physician-led integrated healthcare system, since September 2009 and was a director of MELA Sciences, Inc., a medical device company, from 2003 until 2011. - Breaux B. Castleman，自2013年6月起，他一直担任Isis的董事。自2011年8月起，他担任 Syntiro Healthcare Services, Inc.的总裁和首席执行官，这是一个卫生保健投资公司，最近它将其经营权作为一个综合护理管理和疾病管理的服务供应商出售。自2009年9月起，他担任USMD Holdings, Inc.的董事，这是一个医生领导的综合保健系统公司。自2003年至2011年，他担任 MELA Sciences, Inc.的董事，这是一个医疗设备公司。
- Breaux B. Castleman has served as a Director of Ionis since June 2013. Since August 2001 Mr. Castleman has been president and chief executive officer of Syntiro Healthcare Services, Inc., a healthcare investment company, which sold its operations as a service provider of integrated care management and disease management. Mr. Castleman has been a director of USMD Holdings, Inc., a physician-led integrated healthcare system, since September 2009 and was a director of MELA Sciences, Inc., a medical device company, from 2003 until 2011.
高管简历
中英对照 | 中文 | 英文- Sarah Boyce
Sarah Boyce在2015年1月加入Isis担任Phenomex Inc.的首席商务官。在加入Isis之前（2012-2014年）她是Forest Laboratories股份有限公司（Forest Laboratories, Inc）副总裁和国际商务战略和运营负责人。2010-2011年她是Alexion Pharmaceuticals副总裁和肾脏病治疗领域的全球负责人。2000-2010年她在Novartis Group AG担任不同的职位，包括副总裁，儿科与专业的全球项目负责人。在那之前，她在Bayer Pharmaceuticals and Roche担任不同职位。
Sarah Boyce,has served as President and Chief Executive Officer of Avidity Biosciences, Inc., a publicly-traded biotechnology company, since October 2019. Prior to joining Avidity, she served as a Director and President of Akcea Therapeutics (Nasdaq: AKCA), a publicly-traded biopharmaceutical company focused on serious and rare diseases, from April 2018 through September 2019. Ms. Boyce served as Chief Business Officer at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) from January 2015 to April 2018, where she was responsible for business development, alliance management, patient advocacy and investor relations. Prior to joining Ionis, she served as Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc. Ms. Boyce held various positions with Alexion Pharmaceuticals Inc., Novartis Group AG (NYSE: NVS), Bayer AG and F. Hoffmann-La Roche AG. Ms. Boyce also served on the board of directors of Berkeley Lights Inc. (Nasdaq: BLI), a publicly-held biopharmaceutical company, from July 2019 until May 2022.Ms. Boyce received a B.S. degree in microbiology from the University of Manchester, England.- Sarah Boyce在2015年1月加入Isis担任Phenomex Inc.的首席商务官。在加入Isis之前（2012-2014年）她是Forest Laboratories股份有限公司（Forest Laboratories, Inc）副总裁和国际商务战略和运营负责人。2010-2011年她是Alexion Pharmaceuticals副总裁和肾脏病治疗领域的全球负责人。2000-2010年她在Novartis Group AG担任不同的职位，包括副总裁，儿科与专业的全球项目负责人。在那之前，她在Bayer Pharmaceuticals and Roche担任不同职位。
- Sarah Boyce,has served as President and Chief Executive Officer of Avidity Biosciences, Inc., a publicly-traded biotechnology company, since October 2019. Prior to joining Avidity, she served as a Director and President of Akcea Therapeutics (Nasdaq: AKCA), a publicly-traded biopharmaceutical company focused on serious and rare diseases, from April 2018 through September 2019. Ms. Boyce served as Chief Business Officer at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) from January 2015 to April 2018, where she was responsible for business development, alliance management, patient advocacy and investor relations. Prior to joining Ionis, she served as Vice President, Head of International Business Strategy and Operations at Forest Laboratories, Inc. Ms. Boyce held various positions with Alexion Pharmaceuticals Inc., Novartis Group AG (NYSE: NVS), Bayer AG and F. Hoffmann-La Roche AG. Ms. Boyce also served on the board of directors of Berkeley Lights Inc. (Nasdaq: BLI), a publicly-held biopharmaceutical company, from July 2019 until May 2022.Ms. Boyce received a B.S. degree in microbiology from the University of Manchester, England.
- B. Lynne Parshall
B. Lynne Parshall， 2013年2月起担任董事会成员。她目前担任Ionis Pharmaceuticals， Inc.和Foghorn Therapeutics Inc.的董事会成员。Parshall女士于1991年至2017年在Ionis任职，在那里她担任过各种职务。在加入Ionis之前，她是Cooley LLP律师事务所的合伙人。Parshall女士自2021年12月起担任私营生命科学公司Repetoir Immune Medicines， Inc.的董事会成员；自2022年3月起担任私营生命科学公司Ring Therapeutics的董事会成员；自2022年8月起担任Foghorn Therapeutics的董事会成员；自2023年起担任私营公司Alltrna和Celdeara Medical的董事会成员。Parshall女士从2015年到2020年10月担任Akcea Therapeutics Inc.的董事会成员。Parshall女士是the Licensing Executives Society的成员，也是美国、加州和圣地亚哥律师协会的成员。她拥有斯坦福大学法学院的法学博士学位和哈佛大学的学士学位。
B. Lynne Parshall,has served as a member of Board of Directors since February 2013. She currently serves as a member of the Board of Directors of Ionis Pharmaceuticals, Inc. and Foghorn Therapeutics Inc. Ms. Parshall was employed at Ionis from 1991 to 2017 where she held various positions of increasing responsibility. Prior to joining Ionis, she was a partner at the law firm of Cooley LLP. Ms. Parshall has served on the Board of Directors of Repetoir Immune Medicines, Inc., a private life sciences company, since December 2021, Ring Therapeutics, a private life sciences company, since March 2022 and Foghorn Therapeutics since August 2022 and each of Alltrna and Celdeara Medical, both private companies, since 2023. Ms. Parshall served as a member of the Board of Directors of Akcea Therapeutics Inc. from 2015 to October 2020. Ms. Parshall is a member of the Licensing Executives Society and a member of the American, California and San Diego bar associations. She holds a J.D. from Stanford Law School and a B.A. from Harvard University.- B. Lynne Parshall， 2013年2月起担任董事会成员。她目前担任Ionis Pharmaceuticals， Inc.和Foghorn Therapeutics Inc.的董事会成员。Parshall女士于1991年至2017年在Ionis任职，在那里她担任过各种职务。在加入Ionis之前，她是Cooley LLP律师事务所的合伙人。Parshall女士自2021年12月起担任私营生命科学公司Repetoir Immune Medicines， Inc.的董事会成员；自2022年3月起担任私营生命科学公司Ring Therapeutics的董事会成员；自2022年8月起担任Foghorn Therapeutics的董事会成员；自2023年起担任私营公司Alltrna和Celdeara Medical的董事会成员。Parshall女士从2015年到2020年10月担任Akcea Therapeutics Inc.的董事会成员。Parshall女士是the Licensing Executives Society的成员，也是美国、加州和圣地亚哥律师协会的成员。她拥有斯坦福大学法学院的法学博士学位和哈佛大学的学士学位。
- B. Lynne Parshall,has served as a member of Board of Directors since February 2013. She currently serves as a member of the Board of Directors of Ionis Pharmaceuticals, Inc. and Foghorn Therapeutics Inc. Ms. Parshall was employed at Ionis from 1991 to 2017 where she held various positions of increasing responsibility. Prior to joining Ionis, she was a partner at the law firm of Cooley LLP. Ms. Parshall has served on the Board of Directors of Repetoir Immune Medicines, Inc., a private life sciences company, since December 2021, Ring Therapeutics, a private life sciences company, since March 2022 and Foghorn Therapeutics since August 2022 and each of Alltrna and Celdeara Medical, both private companies, since 2023. Ms. Parshall served as a member of the Board of Directors of Akcea Therapeutics Inc. from 2015 to October 2020. Ms. Parshall is a member of the Licensing Executives Society and a member of the American, California and San Diego bar associations. She holds a J.D. from Stanford Law School and a B.A. from Harvard University.
- C. Frank Bennett
C. Frank Bennett，2006年1月，他晋升为反义研究部门的高级副总裁。自1995年6月至2006年1月，他担任我们的研究部们副总裁。自1993年3月至1995年6月，他担任分子药理学部门主管；自1992年5月至1993年3月，他担任分子和细胞生物学部门的副主管。在1989年加入Isis之前，他任职于SmithKline and French Laboratories ，担任许多研究性的职务。他是新加坡Experimental Therapeutics Center的科学顾问董事会的外部成员。
C. Frank Bennett was promoted to Senior Vice President, Antisense Research in January 2006. From June 1995 to January 2006 Dr. Bennett served as our Vice President, Research. From March 1993 to June 1995 he was Director, Molecular Pharmacology, and from May 1992 to March 1993 he was an Associate Director in our Molecular and Cellular Biology department. Prior to joining Ionis in 1989 Dr. Bennett was employed by SmithKline and French Laboratories in various research positions. He is an external member of the Scientific Advisory Board of Experimental Therapeutics Center in Singapore.- C. Frank Bennett，2006年1月，他晋升为反义研究部门的高级副总裁。自1995年6月至2006年1月，他担任我们的研究部们副总裁。自1993年3月至1995年6月，他担任分子药理学部门主管；自1992年5月至1993年3月，他担任分子和细胞生物学部门的副主管。在1989年加入Isis之前，他任职于SmithKline and French Laboratories ，担任许多研究性的职务。他是新加坡Experimental Therapeutics Center的科学顾问董事会的外部成员。
- C. Frank Bennett was promoted to Senior Vice President, Antisense Research in January 2006. From June 1995 to January 2006 Dr. Bennett served as our Vice President, Research. From March 1993 to June 1995 he was Director, Molecular Pharmacology, and from May 1992 to March 1993 he was an Associate Director in our Molecular and Cellular Biology department. Prior to joining Ionis in 1989 Dr. Bennett was employed by SmithKline and French Laboratories in various research positions. He is an external member of the Scientific Advisory Board of Experimental Therapeutics Center in Singapore.
- Richard S. Geary
Richard S. Geary，2008年8月，他晋升为开发部门高级副总裁。自2003年8月至2008年8月，他担任我们临床开发部门的副总裁。自1995年11月至2003年8月，他在临床前开发部门担任过许多职务。在1995年加入Isis之前，他是Southwest Research Institute。的高级研究科学家和应用化学部门的生物分析和临床前药物动力小组的领导。
Richard S. Geary was promoted to Senior Vice President, Development in August 2008. From August 2003 to August 2008 Dr. Geary served as our Vice President, Preclinical Development. From November 1995 to August 2003 he held various positions within the Preclinical Development department. Prior to joining Ionis in 1995 Dr. Geary was Senior Research Scientist and Group Leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute.- Richard S. Geary，2008年8月，他晋升为开发部门高级副总裁。自2003年8月至2008年8月，他担任我们临床开发部门的副总裁。自1995年11月至2003年8月，他在临床前开发部门担任过许多职务。在1995年加入Isis之前，他是Southwest Research Institute。的高级研究科学家和应用化学部门的生物分析和临床前药物动力小组的领导。
- Richard S. Geary was promoted to Senior Vice President, Development in August 2008. From August 2003 to August 2008 Dr. Geary served as our Vice President, Preclinical Development. From November 1995 to August 2003 he held various positions within the Preclinical Development department. Prior to joining Ionis in 1995 Dr. Geary was Senior Research Scientist and Group Leader for the bioanalytical and preclinical pharmacokinetics group in the Applied Chemistry Department at Southwest Research Institute.
- Stanley T. Crooke
Stanley T. Crooke, M.D., Ph.D.，2009年1月我们公司成立，他在我们董事会任职。此前2007年11月以来，他担任Regulus Therapeutics LLC的董事。他加入我们董事会并担任伊希斯的代表并在2009年1月1日或我们创立投资者权利协议时，他按照建立投资者权利协议进行投资（Alnylam和Isis）。他是Isis的创始人，并担任其首席执行官和董事（1989年以来）以及董事长（1991年以来）。他获得贝勒医学院（Baylor College of Medicine） 药物学硕士和博士学位以及巴特勒大学（Butler University）的药物学学士学位。
Stanley T. Crooke is a founder of Ionis and has been Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Ionis, from 1980 until January 1989 Dr. Crooke was employed by SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories.- Stanley T. Crooke, M.D., Ph.D.，2009年1月我们公司成立，他在我们董事会任职。此前2007年11月以来，他担任Regulus Therapeutics LLC的董事。他加入我们董事会并担任伊希斯的代表并在2009年1月1日或我们创立投资者权利协议时，他按照建立投资者权利协议进行投资（Alnylam和Isis）。他是Isis的创始人，并担任其首席执行官和董事（1989年以来）以及董事长（1991年以来）。他获得贝勒医学院（Baylor College of Medicine） 药物学硕士和博士学位以及巴特勒大学（Butler University）的药物学学士学位。
- Stanley T. Crooke is a founder of Ionis and has been Chief Executive Officer and a Director since January 1989. He was elected Chairman of the Board in February 1991. Prior to founding Ionis, from 1980 until January 1989 Dr. Crooke was employed by SmithKline Beckman Corporation, a pharmaceutical company, where his titles included President of Research and Development of SmithKline and French Laboratories.
- Elizabeth L. Hougen
Elizabeth L. Hougen，2013年1月，她晋升为财务高级副总裁和首席财务官。自2007年1月至2012年12月，她担任我们的财务副总裁和首席会计官；自2000年5月至2007年1月，她担任我们的财务副总裁。在2000年加入Isis之前，她是 Molecular Biosystems, Inc.的财务执行董事和首席财务官，这是一个上市的生物技术公司。
Elizabeth L. Hougen was promoted to Senior Vice President, Finance and Chief Financial Officer in January 2013. From January 2007 to December 2012 Ms. Hougen served as our Vice President, Finance and Chief Accounting Officer and from May 2000 to January 2007 she served as our Vice President, Finance. Prior to joining Ionis in 2000 Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.- Elizabeth L. Hougen，2013年1月，她晋升为财务高级副总裁和首席财务官。自2007年1月至2012年12月，她担任我们的财务副总裁和首席会计官；自2000年5月至2007年1月，她担任我们的财务副总裁。在2000年加入Isis之前，她是 Molecular Biosystems, Inc.的财务执行董事和首席财务官，这是一个上市的生物技术公司。
- Elizabeth L. Hougen was promoted to Senior Vice President, Finance and Chief Financial Officer in January 2013. From January 2007 to December 2012 Ms. Hougen served as our Vice President, Finance and Chief Accounting Officer and from May 2000 to January 2007 she served as our Vice President, Finance. Prior to joining Ionis in 2000 Ms. Hougen was Executive Director, Finance and Chief Financial Officer for Molecular Biosystems, Inc., a public biotechnology company.
- Brett P. Monia
Brett P. Monia ，2012年1月，他晋升为药物研发部门和公司发展部门的高级副总裁。自2009年2月至2012年1月，他担任我们的药物研发部门和公司发展部门的副总裁；自2000年10月至2009年2月，他担任临床前药物开发部门的副总裁。自1989年10月至2000年10月，他在分子药理学部门担任过许多职务。
Brett P. Monia was promoted to Senior Vice President, Drug Discovery and Corporate Development in January 2012. From February 2009 to January 2012 Dr. Monia served as our Vice President, Drug Discovery and Corporate Development and from October 2000 to February 2009 he served as our Vice President, Preclinical Drug Discovery. From October 1989 to October 2000 he held various positions within our Molecular Pharmacology department.- Brett P. Monia ，2012年1月，他晋升为药物研发部门和公司发展部门的高级副总裁。自2009年2月至2012年1月，他担任我们的药物研发部门和公司发展部门的副总裁；自2000年10月至2009年2月，他担任临床前药物开发部门的副总裁。自1989年10月至2000年10月，他在分子药理学部门担任过许多职务。
- Brett P. Monia was promoted to Senior Vice President, Drug Discovery and Corporate Development in January 2012. From February 2009 to January 2012 Dr. Monia served as our Vice President, Drug Discovery and Corporate Development and from October 2000 to February 2009 he served as our Vice President, Preclinical Drug Discovery. From October 1989 to October 2000 he held various positions within our Molecular Pharmacology department.
- Patrick R. O'Neil
Patrick R. O'Neil，2013年1月，他被晋升为法律部们高级副总裁和总法律顾问。自2010年9月至2013年1月，他担任我们的法律部门副总裁和总法律顾问；自2009年1月至2010年9月，他担任我们的法律部门副总裁和高级法律事务顾问。自2001年10月至2009年1月，他在我们的法律部门担任过各种职务。在加入Isis之前，他是 Cooley LLP。的助理。
Patrick R. O'Neil was promoted to Senior Vice President, Legal and General Counsel in January 2013. From September 2010 to January 2013 Mr. O'Neil served as our Vice President, Legal and General Counsel and from January 2009 to September 2010 he served as our Vice President, Legal and Senior Transactions Counsel. From October 2001 to January 2009 he held various positions within our Legal department. Prior to joining Isis, Mr. O'Neil was an associate at Cooley LLP.- Patrick R. O'Neil，2013年1月，他被晋升为法律部们高级副总裁和总法律顾问。自2010年9月至2013年1月，他担任我们的法律部门副总裁和总法律顾问；自2009年1月至2010年9月，他担任我们的法律部门副总裁和高级法律事务顾问。自2001年10月至2009年1月，他在我们的法律部门担任过各种职务。在加入Isis之前，他是 Cooley LLP。的助理。
- Patrick R. O'Neil was promoted to Senior Vice President, Legal and General Counsel in January 2013. From September 2010 to January 2013 Mr. O'Neil served as our Vice President, Legal and General Counsel and from January 2009 to September 2010 he served as our Vice President, Legal and Senior Transactions Counsel. From October 2001 to January 2009 he held various positions within our Legal department. Prior to joining Isis, Mr. O'Neil was an associate at Cooley LLP.